lntegrins are central t o many aspects of the tissue localization of normal and malignant lymphocytes. We examined how integrin function, rather than simple expression, might determine disease behavior in chronic lymphocytic leukemia (CLL). Using fluorescence-activated cell sorting (FACS) and immunoprecipitation, we first established the precise integrin heterodimer expression of a representative group of CLL patients (p1 consistently present, with variable (~3 , (~4 , and a5; a4p7 often expressed; aLp2 high; aVp3 absent). Regarding function, we initially examined the ability of CLL cells t o interact with endothelium, because such interaction is the initial event determining the entry of CLL lymphocytes into tissues. The abnormal lymphocytes were shown t o bind at low levels t o unstimulated endothelium via p2/intercellular adhesion molecule (ICAM). However, when the endothelium was stimulated, markedly enhanced interaction with endothelium was observed in approximately half the cases; in these patients, the neoplastic population expressed a4p1, OST NORMAL and malignant lymphocytes are recir-M culating cells. Such recirculation requires that the cell be able to traverse endothelium and undergo controlled migration within tissues. The integrins are a family of heterodimeric adhesion receptors that are central to both these processes.'.* Different heterodimers confer the ability to recognize and respond to a range of both cell-expressed and extracellular matrix ligands. ' We have recently shown that integrin expression and function are important in the migratory behavior of the hairy cells (HCs) of hairy-cell leukemia (HCL).4-6 In particular, we have shown that specific heterodimers determine the response of the malignant cell to adhesive proteins present in the extracellular matrix of the tissues typically involved in HCL.'.'
(~4 , and a5; a4p7 often expressed; aLp2 high; aVp3 absent). Regarding function, we initially examined the ability of CLL cells t o interact with endothelium, because such interaction is the initial event determining the entry of CLL lymphocytes into tissues. The abnormal lymphocytes were shown t o bind at low levels t o unstimulated endothelium via p2/intercellular adhesion molecule (ICAM). However, when the endothelium was stimulated, markedly enhanced interaction with endothelium was observed in approximately half the cases; in these patients, the neoplastic population expressed a4p1, OST NORMAL and malignant lymphocytes are recir-M culating cells. Such recirculation requires that the cell be able to traverse endothelium and undergo controlled migration within tissues. The integrins are a family of heterodimeric adhesion receptors that are central to both these processes.'.* Different heterodimers confer the ability to recognize and respond to a range of both cell-expressed and extracellular matrix ligands. ' We have recently shown that integrin expression and function are important in the migratory behavior of the hairy cells (HCs) of hairy-cell leukemia (HCL). [4] [5] [6] In particular, we have shown that specific heterodimers determine the response of the malignant cell to adhesive proteins present in the extracellular matrix of the tissues typically involved in HCL.'. ' Others have examined integrin expression of chronic lymphocytic leukemia (CLL) cells and related the findings to the clinical behavior of the disease.'.' No consistent conclusions have emerged, although individual studies have suggested that the presence of certain chains may have prognostic significance and may influence tissue distribution.'"." However, these previous studies of CLL have not determined detailed integrin heterodimer associations or examined in vitro cell responses to ligand binding.
Therefore we examined integrin expression and function in CLL in the light of insights gained during our recent studies
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Submitted August 30, 1995; uccepted Januav 23, 1996 which conferred the ability t o adhere strongly t o stimulated endothelium via the a 4 p l ligand, vascular cellular adhesion molecule-1 (VCAM-1). In relation t o the migration of CLL cells within tissues, the abnormal lymphocytes showed differential binding t o various adhesive proteins; they did not attach t o basement membrane components, but displayed variable adhesion t o fibronectin (FNI. Finally, we examined the role of cell activation in these processes, and showed that activated CLL lymphocyte populations showed an increased capacity t o adhere to both endothelium and matrix. Moreover, ex vivo CLL cells showed no capacity t o migrate through endothelium/stroma, but were able t o do so after cytokine stimulation. These studies show how the constitutive integrin expression/function, the intrinsic activation state of the cell, and the capacity of cytokines t o modify integrin-mediated function all combine t o determine the different patterns of clinical disease observed in CLL. of HCL. Thus, we sought to establish the precise heterodimer associations displayed by a group of typical CLL patients. We examined how these integrin receptors influence the response of the CLL cell both to extracellular matrix and to endothelium. Finally, because our previous studies of HCL emphasized the importance of B-cell activation in integrinmediated responses and because CLL cells are known to display different degrees of activation," we related our observations to the activation phenotype of the CLL cases.
SUBJECTS AND METHODS

Cell Sources and Cell Culture
Patient Material
Ten morphologically typical cases of CLL were used in this study. In all cases. the cells expressed low-density, light-chain-restricted surface Ig, high CD5, and low CD22. The pertinent clinical features of these patients are shown in Table I 
Antibodies and Immunologic Techniques
Monoclonal Antibodies (MoAbs) and Probes
Anti-aV and $3 (clones 13C1 and 1076, respectively) were kind gifts from Professor G.F. Burns (Newcastle, New South Wales, Australia). SE8 against the a2-chain was a kind gift from Dr R. Bankert 
APAAP/Immunoperoxidase
APAAP reagents (Dakopatts, Copenhagen, Denmark) were used according to standard protocols. Immunoperoxidase staining was performed with a Sigma ExtrAvidin kit according to the recommended protocol, with detection via o-phenylene diamine (OPD).
Triple-Layer Fluorescence-Activated Cell Sorting
Purified leukemic cells were incubated with primary antibody for 10 minutes at room temperature. The second layer was 200 pglmL biotin-conjugated horse anti-mouse Ig (Becton Dickinson), incubated for 10 minutes (room temperature). The fluorochrome was phycoerythrin conjugated to streptavidin (Becton Dickinson). Detection was performed on a Becton Dickinson fluorescence-activated cell sorting (FACS) Analyzer; 5,000 events were recorded and analyzed using Consort 30 software (Becton Dickinson).
Immunoprecipitation
Highly purified CLL or HCL cells ("2 X IO') were surfacelabeled with 0.5 mCi Iz5I by a lactoperoxidase technique using glucose oxidase to generate hydrogen peroxide according to published methods. These were lysed in 1% Nonidet P-40 lysis buffer in the presence of freshly prepared enzyme inhibitors (aprotinin 10 pgl mL, phenylmethylsulfonyl fluoride 2 mmol/L, and E64 10 pmol/L). Cellular debris was removed by centrifugation, and the solubilized material was extensively precleared with protein G Sepharose (Pharmacia, Milton Keynes, UK) alone (twice) and in the presence of irrelevant IgGl MoAbs (twice). The precleared samples were then specifically immunoprecipitated using anti-integrin or class-specific control antibodies. Samples were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (8% gel) and detection by autoradiography.
Adhesion Studies
Adhesive Proteins
The purity of proteins used in this study was greater than 95% as determined by SDS-PAGE.
Fibronectin. Fibronectin (FN) was purified by gelatin-Sepharose affinity chromatography according to the method of Engvall and Ruoslahti'6 (fresh frozen plasma unsuitable for human therapeutic use was provided by BTS, Liverpool, UK).
Human vitronectin (VN), laminin, and type I collagen were purchased from Sigma Chemical CO (St Louis, MO).
An extract of basement membrane containing entactin, collagen, and laminin was purchased from Promega Ltd (Madison, WI).
Vitronectin, laminin, and collagen.
ECL cell attachment matrix.
Adhesion Assay
Wells were prepared as follows. HUVEC, splenic red-pulp fibroblasts (outgrowth from HCL spleen, used at fifth passage; kindly donated by K. Till), or bone marrow (BM) fibroblasts (grown from long-term BM culture after 6 weeks; kindly donated by R. Harris) were seeded into sterilized 96-well (Falcon Microtest 111 Flexible; Falcon, Oxford, UK) assay plates that had been coated with ECL attachment matrix. When confluent, the cells were stimulated for different periods using 10 U/mL tumor necrosis factor alpha (TNFa) (Sigma); cell layers were thoroughly rinsed with medium before addition of CLL or HCL cells to remove TNFa. Adherence to matrix proteins was measured in similar wells coated with 40 pg/mL purified FN, laminin, ECL, or collagen overnight at 4°C.' -0 nine-free RPMI (GIBCO) containing 20 to 30 pCi 35S-methionine (Amersham, Bucks, UK). After extensive washing, 2 X lo5 cells in 100 pL RPMI without serum were added to wells and allowed to adhere for 15 minutes at 37°C. Wells were then gently topped with warm medium, sealed, inverted, and centrifuged at 250g for 5 minutes. After centrifugation, the medium was gently aspirated and replaced with warm iso-osmotic fixative. After 5 minutes, wells were rinsed with phosphate-buffered saline, scintillant was added, and cells were counted in a microbeta plate counter (Wallac 1450 liquid scintillation counter; Wallac, Milton Keynes, UK). Adhesion was calculated as a percentage of total counts due to 2 X lo5 cells. The number of cells used in this assay produces a ratio of lymphocytes to endothelial cells of 8: 1 and allows the B cells to form a monolayer in the well.
Image Analysis scribed previously?
Investigation of cytoskeletal responses to adhesion has been de-
Activation of CLL
Determination of Activation Phenotype of Ex Vivo CLL
A panel of recognized B-cell activation markers were used. These were CD39, CD71, CD80, CD49e. and CDl IC (all defined as present or absent by FACS) plus CD23 and CD25 (defined as high or intermediate expression by FACS). Cases were scored according to the number of activation markers present. Those displaying at least five markers of activation were arbitrarily designated as activated cases.
In Vitro Activation
Various known B-cell activators were used to assess the integrinmediated behavior of CLL cells after exogenous stimulation. These were TNFa (100 ng/mL), TNFa (10 ng/mL) combined with PMA (1 ng/mL), interleukin-4 ([IL-41 3 ng/mL; Sigma), IL-10 (10 ng/mL; Genzyme), or SAC (0.001%; Calbiochem Ltd, Nottingham, UK), all added to a suspension of CLL cells for 2 or 24 hours before the assay.
RESULTS
Integrin Chain Expression by CLL Cells
Detection was performed using both APAAF' and a sensitive triple-layer streptavidin-biotin FACS technique. Such triple-layer detection systems have previously been successfully used in CLL because they enhance sensitivity and allow low and intermediate expression of integrins to be identified.17 For comparison, HC integrin expression was examined in an identical way. Positive expression was regarded as a unimodal shift to the right relative to the isotypic control on FACS analysis. Similar results were obtained using both APAAP and FACS.
The shared pl chain that defines the very late activation antigen family was demonstrable by FACS on all cases and was confirmed by APAAP. However, the intensity of staining varied from case to case, and when expressed as a percent of cells to the right of the isotypic control, 23% to 92% of lymphocytes were positive. Among the hematologically important a chains, a3, a4, and a5 were variably expressed (Fig lA) , but a 2 and a6 were not demonstrable. However, although a3, a4, and a5 could all be expressed. the relative proportions of the three chains differed p l Integrins. considerably between cases. In contrast, HCs consistently possessed high levels of a 4 and a5, and a 3 expression was low or absent.6 Because a 4 is widely recognized as an important determinant of B-cell behavior and because it can associate with either of two /3 chains (pl or /37), immunoprecipitations with antLa4 MoAb were performed to look for coprecipitated p chain(s). In CLL, a 4 was clearly shown to form heterodimers with both pl and @7 (Fig 2) . In contrast, in HCL, a4 only associated with p16 (data not shown).
p2 Integrins. In CLL, the p2 chain was consistently present. Regarding associated a chains, a typical profile could be identified, namely aL+, ax-, with variable a M expression (Fig 1B) . In HCL, a reciprocal pattern is seen (aL-, aX+),I3 and this was confirmed here.
In none of 10 CLL cases studied were p 3 or aV detected. This was in marked contrast to HCL, in which aVP3 was consistently expressed.
a4-Chain associations.
p3 Integrins.
For 
6
Integrin expression, as well as function, is closely linked to cell activation. HCs consistently display an activated cell phenotype, and this is probably reflected in their uniformly high expression of certain integrin chains." CLL cells also show features of activation; however, these not only differ from those observed in HCL, but also vary from case to case.'? Therefore we examined the proposition that activation plays a role in the variable integrin expression displayed in different cases of CLL.
Regarding ex vivo expression of PI and 02 integrins, there
was no correlation between levels of a chain and activation a s determined by expression of antigens detected by at least five of a panel of seven MoAbs against B-cell activation markers (Fig I A and B) . Furthermore, following in vitro activation with various stimuli, CLL cells did not show a consistent alteration of integrin expression after up to 24 hours.
Binding of CLL Cells to Endothelium and Matrix
The ability of a circulating cell to interact with endothelium is the principal requirement for initial localization to a given tissue, and is a prerequisite for subsequent cell migration into the stroma of that tissue. Therefore we used HU-VEC, BM stromal cells, and purified adhesive proteins to examine the capacity of CLL cells to bind to these various elements.
CLL cells bound poorly to unstimulated HUVEC (under identical conditions, 10% to 25% of CLL cells v 35% to 60% of HCs became adherent). Following stimulation of the endothelium with TNFa, a subgroup of CLL patients (4 of 10) displayed markedly enhanced binding, whereas the remaining patients continued to show low levels of adhesion.
Regarding the ligands involved in such binding, a number of endothelial adhesion molecules are potentially involved (principally ICAM, P-selectin, E-selectin, and VCAM-1). In our endothelial model, only ICAM was expressed in the absence of TNFa stimulation (Fig 3) . This suggested that the ICAM-binding integrin, aLP2, consistently expressed by all our CLL cases was responsible (via ICAM) for the baseline adhesion to endothelium. This was confirmed by the observation that anti-aLP2 MoAb inhibited binding (by 43%
? 4%, n = 4).
The four cases that showed enhanced binding to stimulated endothelium were the only patients in whom CLL cells expressed a 4 chains. Moreover, the time course of the enhanced binding closely paralleled the appearance of VCAM-1 on the stimulated endothelium (Fig 4) . In contrast, changes in the other endothelial ligands (P-selectin, E-selectin, and ICAM) did not parallel the observed increased levels of binding (Fig 3) . Furthermore, blocking MoAbs against Eselectin and ICAM did not inhibit the enhanced adhesion of CLL cells to stimulated endothelium, whereas anti-VCAMAdhesion to endothelium. In those expressing a4, markedly enhanced binding was observed when the endothelium was stimulated with TNFa (reprMsntative example shown, a4' CLL). This increased binding closely paralleled the increased VCAM-1 expression induced by TNFa; other relevant adhesion molecules (ICAM-1, P-selectin, and E-sf#lectinl did not paralle1 the CLL binding (Fig 3) . TNFa was removed by thorough washing before addition of CLL cells.
1 antibody strongly inhibited binding ( Table 2) . These findings indicate that a4P1 mediates CLL cell binding to VCAM-1 -expressing endothelium and that the integrin is in an active form. Therefore, in the a4-expressing subgroup of CLL patients, the abnormal lymphocytes have the potential to show specific tissue-binding properties.
CLL cells showed a minimal capacity to adhere to collagen and laminin, both important constituents of basement membranes. However, in all cases, the cells displayed some capacity to adhere to FN; such binding was variable (Fig 5) . HCs exhibited similar low levels of binding to collagen and laminin, but adhered to FN in a strong and uniform manner (Fig 5) . 
Adhesion to matrix.
Relationship of Integrin Function to Activation
Although earlier herein we found no correlation between integrin a chain expression and activation phenotype, it seemed relevant to also examine integrin-mediated functional responses in relation to activation.
Using the same phenotypic criteria of activation as in the previous section (defined earlier), we showed a significant association between activation and adherence both to unstimulated HUVEC and to FN (Fig 5) . Because CLL binding to unstimulated HUVEC is mediated via aLP2IICAM interaction, these findings suggest that the aLP2 integrin on CLL cells is capable of further functional activation. A similar conclusion is likely concerning the FN receptors (a3P1, a4P1, and cySP1) potentially involved in activation-related binding of CLL cells to FN.
Representative cases of activated and nonactivated phenotype were examined for adhesive responses following in vitro stimulation using SAC. After stimulation, both activated and nonactivated cases significantly increased adhesion both to FN and to endothelial cells (Fig 6) . This confirmed that activation is important in CLL cell adhesion.
Ex vivo CLL cells.
In vitro-stimulated CLL cells.
Functional Responses of CLL Cells to Integrin-Mediated Binding
Cell binding to endothelium and matrix is a prerequisite for functional responses such as migration and spreading that occur within tissues, but may or may not be followed by such responses. Integrin-mediated binding may be followed by a range of functional consequences, but we have focused on the cytoskeletal changes that are a major determinant of tissue migration. Thus, we first examined shapechange in response to matrix binding, and then determined the capacity of the malignant cell to migrate under endothelial or BM stromal cells.
We ever, when stimulated with IL-10, the cells acquired the ability to migrate under the stromal cells layers (Fig 7) . In contrast, HCs showed a comparable capacity for transmigration without prior stimulation with cytokine (Fig 7) .
DISCUSSION
The present studies have defined the integrin expression of CLL lymphocytes in more detail than previously reported.
Thus, the cells were shown consistently to express Pl in association with a3, a4, or a5. However, there was considerable variation in the expression of these three a chains from case to case, and the level of a particular chain did not necessarily correlate with levels of the other two. This variable pattern of expression was different from the consistent pattern observed in HCL, in which a4 and a5 were always present at high levels and a3 was low or absent.
Our findings in CLL are broadly in keeping with those of nodal malignancies, HCL and myeloma, the abnormal cells consistently lack the heterodimer?" It is therefore tempting to speculate that a407 is important in the localization of malignant lymphoid cells to the lymph node.
Our immunophenotypic data on p 2 integrins are largely in keeping with previous studies. Thus, CLL cells express a L p 2 but generally lack aXp2'"."; the converse is true in HCL." Both CLL cells and HCs displayed variable levels of aMP2. Regarding 0 3 expression. we showed that the integrin was not present on the lymphocytes of any cases of CLL studied. This was in marked distinction to HCL, for which a V p 3 is consistently demonstrable and mediates cell motility.' Our findings conceming p 3 differ slightly from those reported by De Rossi et al. ' wherein a minority (-15%) of patients expressed this chain at low levels. However, many of their p3-positive cases were noted to be CD5-. Because we specifically excluded CDS-cases from our study, it is perhaps not surprising that our group of patients did not include an aVfl3-expressing case.
Having established the integrin profile of CLL cells. we went on to investigate the functional interactions mediated by these receptors-an area not previously explored in CLL. We first examined the ability of the malignant cells to bind to endothelium. Variable but low levels of binding were consistently observed, and this was shown to be mediated via aLp2nCAM interactions. However, when the endothelium was stimulated with TNFa. two pattems of adhesion were observed. In four of IO cases studied, lymphocyte adhesion was markedly enhanced; this enhanced binding was shown to be mediated by a4pINCAM-I interaction. In the six cases in which no enhanced adhesion to stimulated endothelium was observed, CLL cells lacked a4p1. Overall, these results indicate not only that CLL cells from individual cases differ in integrin expression, but also that these differences can affect the functional capabilities of the cell. This may have important clinical consequences. For example, in a given case of CLL, the presence of a4pI may confer on the malignant population a propensity to localize at major sites of VCAM-I expression, including BM, liver, and
Having examined the binding of CLL cells to endothelium, we next investigated their ability to interact with important adhesive proteins of the extracellular matrix. Therefore, we compared the adhesive capacity of CLL cells and HCs in a standardized distraction assay of adhesion." CLL lymphocytes did not adhere to basement membrane proteins (laminin, collagen, and entactin), but were able to bind the stromal adhesive protein, FW. However, such binding was variable and was not correlated with the level of expression of any particular FN-binding integrin (a3pl. a4b1, or a 5 p l ) . In contrast, HCs were able to bind to laminin, and adherence to FN was consistently high. We suggest that these findings reflect the different in vivo behavior of CLL and HCL. Thus, HCs show a strong propensity to localize in stroma (eg, the splenic red pulp) and along basement membrane." In contrast, CLL cells do not associate with basement membrane, and tissue involvement (eg, splenic or hepatic infiltration) varies greatly from case to case."
The consistent expression and activity of HC integrins is probably related to the uniformly activated nature of the malignant cells.'' Therefore we examined the hypothesis that the variable degrees of activation observed in different cases For personal use only. on November 16, 2017 . by guest www.bloodjournal.org From of CLL might underlie the variability of integrin-mediated behavior observed in the present study. For this, we used a panel of seven recognized B-cell activation antigens to divide CLL patients according to degree of activation. Arbitrarily, we defined activated cases as those expressing five or more of the panel of antigens. There was no correlation between integrin chain expression and activation as defined earlier. However, we did show a clear correlation between activation state and adhesive behavior. This correlation was particularly marked with respect to adhesion to matrix. The concept that activation is an important determinant of CLL adhesion was further examined by stimulating CLL cells in vitro. These experiments showed that such stimulation increased the adhesion of cells from all cases studied without affecting the level of integrin chain expression. These studies of activation, taken together, indicate that although both qualitative and quantitative integrin expression influence the behavior of CLL cells, such behavior is highly dependent on the activation state of the cells from any particular case.
Finally, because not only adhesion but also migration is an essential determinant of tissue colonization, we compared the migratory ability of CLL lymphocytes with that of HCs. In no case of CLL examined were the cells able to adopt a polarized morphology or migrate underneath endothelial or stromal cells. In contrast, HCs readily became polarized and migrated beneath both cell types. However, following stimulation with IL-10, a proportion of CLL cells displayed a polarized morphology and acquired the ability to migrate under endothelial and stromal cells.
In conclusion, the present study has shown that there are clear qualitative and quantitative differences in integrin expression between different cases of CLL. Furthermore, these integrins can mediate different in vitro functional responses. However, the present investigation has also shown that these integrin-mediated responses are strongly modified by the intrinsic activation state of the malignant cell population; this intrinsic activation can be further influenced by local activating factors such as cytokines. It is likely that this complex interplay of the constitutive integrin expression/ function, the intrinsic activation state, and the capacity of cytokines to modify integrin-mediated function determines the different patterns of tissue involvement observed in CLL. This conclusion may partly explain why previous studies have failed to establish a clear relationship in CLL between simple integrin expression and clinical behavior.
The labor-intensive nature of the functional investigations reported herein limited the number of cases of CLL we could examine, and made firm clinical correlations impossible. However, our studies encourage the notion that integrins are highly relevant to the heterogeneity of CLL, but indicate that such heterogeneity is also determined by the intrinsic activation state of the malignant clone and by its ability to encounter and respond to locally produced cytokines.
